H-Index & Metrics Top Publications

H-Index & Metrics

Discipline name H-index Citations Publications World Ranking National Ranking
Medicine H-index 268 Citations 353,592 1,449 World Ranking 8 National Ranking 1

Research.com Recognitions

Awards & Achievements

2014 - Canadian Medical Hall of Fame

Fellow of the American College of Cardiology (ACC)

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Myocardial infarction
  • Disease

Salim Yusuf mainly investigates Internal medicine, Cardiology, Myocardial infarction, Surgery and Stroke. Many of his studies on Internal medicine involve topics that are commonly interrelated, such as Diabetes mellitus. His Cardiology course of study focuses on Ramipril and Telmisartan.

His Myocardial infarction research is multidisciplinary, incorporating elements of Perioperative and Confidence interval. His Surgery study integrates concerns from other disciplines, such as Angiotensin II, Placebo and Risk factor. In his study, which falls under the umbrella issue of Stroke, Bradycardia is strongly linked to Atrial fibrillation.

His most cited work include:

  • Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. (6679 citations)
  • MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary (6382 citations)
  • COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS (3355 citations)

What are the main themes of his work throughout his whole career to date?

Salim Yusuf mainly focuses on Internal medicine, Cardiology, Myocardial infarction, Stroke and Surgery. His study looks at the relationship between Internal medicine and fields such as Diabetes mellitus, as well as how they intersect with chemical problems. In the subject of general Cardiology, his work in Ejection fraction is often linked to In patient, thereby combining diverse domains of study.

His research in Myocardial infarction intersects with topics in Odds ratio, Placebo and Coronary artery disease. The concepts of his Stroke study are interwoven with issues in Aspirin and Epidemiology. Salim Yusuf has included themes like Anesthesia and Clinical trial in his Randomized controlled trial study.

He most often published in these fields:

  • Internal medicine (65.89%)
  • Cardiology (39.14%)
  • Myocardial infarction (25.02%)

What were the highlights of his more recent work (between 2017-2021)?

  • Internal medicine (65.89%)
  • Stroke (20.81%)
  • Cardiology (39.14%)

In recent papers he was focusing on the following fields of study:

His primary areas of investigation include Internal medicine, Stroke, Cardiology, Myocardial infarction and Disease. His work in Aspirin, Hazard ratio, Atrial fibrillation, Heart failure and Randomized controlled trial are all subfields of Internal medicine research. The various areas that Salim Yusuf examines in his Stroke study include Clinical trial, Statin, Blood pressure, Developing country and Cardiac surgery.

His Cardiology study incorporates themes from Diabetes mellitus, Framingham Risk Score and Montreal Cognitive Assessment. His studies deal with areas such as Regimen and Anesthesia as well as Myocardial infarction. His work carried out in the field of Disease brings together such families of science as Prospective cohort study, Epidemiology, Health care and Risk factor.

Between 2017 and 2021, his most popular works were:

  • Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials (219 citations)
  • Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study (179 citations)
  • Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes (127 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Disease
  • Myocardial infarction

The scientist’s investigation covers issues in Internal medicine, Stroke, Cardiology, Hazard ratio and Myocardial infarction. His Internal medicine and Aspirin, Randomized controlled trial, Heart failure, Coronary artery disease and Atrial fibrillation investigations all form part of his Internal medicine research activities. Salim Yusuf interconnects Genetics, Clinical trial, Family medicine, Dabigatran and Evidence-based medicine in the investigation of issues within Stroke.

His work on Revised Cardiac Risk Index as part of his general Cardiology study is frequently connected to In patient, thereby bridging the divide between different branches of science. His Hazard ratio research incorporates themes from Randomization, Prospective cohort study, Proportional hazards model and Cohort study. His work deals with themes such as Regimen, Placebo and Risk assessment, which intersect with Myocardial infarction.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Top Publications

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary

Salim Yusuf.
The Lancet (2002)

9969 Citations

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

Solvd Investigators;Salim Yusuf;Bertram Pitt;Clarence E Davis.
The New England Journal of Medicine (1991)

9943 Citations

COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS

R Altman;L Carreras;R Diaz;E Figueroa.
BMJ (1994)

5838 Citations

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

John Jv McMurray;Jan Östergren;Karl Swedberg;Christopher B Granger.
The Lancet (2003)

3520 Citations

ACC/AHA Guidelines for Coronary Artery Bypass Graft Surgery A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1991 Guidelines for Coronary Artery Bypass Graft Surgery)

Kim A. Eagle;Robert A. Guyton;Ravin Davidoff;Gordon A. Ewy.
Journal of the American College of Cardiology (1999)

3405 Citations

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Jfe Mann;HC Gerstein;S Yusuf.
The Lancet (2000)

3175 Citations

Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation

Stuart J. Connolly;Janice Pogue;Robert G. Hart;Stefan H. Hohnloser.
The New England Journal of Medicine (2009)

3027 Citations

The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years.

M Coutinho;H C Gerstein;Y Wang;S Yusuf.
Diabetes Care (1999)

2566 Citations

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

Marc A Pfeffer;Karl Swedberg;Christopher B Granger;Peter Held.
The Lancet (2003)

2547 Citations

ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group.

R Collins;R Peto;M Flather;S Parish.
The Lancet (1995)

2306 Citations

Profile was last updated on December 6th, 2021.
Research.com Ranking is based on data retrieved from the Microsoft Academic Graph (MAG).
The ranking h-index is inferred from publications deemed to belong to the considered discipline.

If you think any of the details on this page are incorrect, let us know.

Contact us

Top Scientists Citing Salim Yusuf

Gregory Y.H. Lip

Gregory Y.H. Lip

University of Liverpool

Publications: 836

John J.V. McMurray

John J.V. McMurray

University of Glasgow

Publications: 391

Deepak L. Bhatt

Deepak L. Bhatt

Brigham and Women's Hospital

Publications: 344

Gregg C. Fonarow

Gregg C. Fonarow

University of California, Los Angeles

Publications: 263

John G.F. Cleland

John G.F. Cleland

National Institutes of Health

Publications: 251

Christopher B. Granger

Christopher B. Granger

Duke University

Publications: 243

John W. Eikelboom

John W. Eikelboom

Population Health Research Institute

Publications: 240

Karl Swedberg

Karl Swedberg

University of Gothenburg

Publications: 229

Robert M. Califf

Robert M. Califf

Duke University

Publications: 225

Valentin Fuster

Valentin Fuster

Icahn School of Medicine at Mount Sinai

Publications: 221

Scott D. Solomon

Scott D. Solomon

Brigham and Women's Hospital

Publications: 208

Christopher P. Cannon

Christopher P. Cannon

Brigham and Women's Hospital

Publications: 207

Marc A. Pfeffer

Marc A. Pfeffer

Brigham and Women's Hospital

Publications: 200

Aldo P. Maggioni

Aldo P. Maggioni

Heart Care Foundation, ANMCO Research Center, Florence

Publications: 199

Harvey D. White

Harvey D. White

Auckland City Hospital

Publications: 195

Something went wrong. Please try again later.